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Abstract
Background: Functional gastrointestinal disorders (FGIDs) are characterized by chronic/recurrent gastrointestinal
symptoms not related to organic disorders. Due to the limited treatment options and to the perception of subjects
with FGIDs suffering from a food intolerance, in recent years there has been an increase in the self-prescription of
elimination diets, especially gluten free diet (GFD), for the treatment of these disorders. For this reason, we decided
to perform this systematic review with the aim to evaluate the available evidence on the effects of a GFD on
gastrointestinal symptoms, in subjects with FGIDs.
Methods: Cochrane Library and MEDLINE (via PubMed) databases were searched, from inception to March 2018,
using the MeSH terms “functional gastrointestinal disorder OR irritable bowel syndrome AND gluten”. We included
all the clinical trials published in English and evaluating the effects of a GFD in subjects with FGIDs diagnosed
according to the Rome II, III, and IV criteria.
Results: Eleven trials were eligible (3 prospective trials, 8 single or double-blind placebo-controlled trials), with 10/11
trials including adult subjects with irritable bowel syndrome (IBS) or FGIDs. Most of the prospective studies found an
effect of GFD on gastrointestinal symptoms control. Nevertheless, 1 trial failed to find an association between gluten
and GI symptoms when FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) content
was simultaneously reduced in the diet, and 2 trials reported a worsening of symptoms during placebo administration.
The results of the different trials are difficult to compare due to discrepancies in the study protocols regarding the
amount and type of gluten administered, the duration of the gluten challenge, the type of placebo used, and the
duration of the challenge itself.
Conclusions: According to our results, gluten may contribute to the occurrence of gastrointestinal symptoms in
patients with FGIDs, particularly in those with IBS. Nevertheless, the results of the currently available trials are difficult to
compare due to the lack of standardization in the study designs. For this reason, it is still not possible to recommend
the use of the GFD in the routine management of FGIDs.
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Background
Functional gastrointestinal disorders (FGIDs) define a group
of chronic or recurrent gastrointestinal symptoms, not ex-
plained by known organic disorders [1]. The pathogenesis of
FGIDs is multifactorial, with several mechanisms contribut-
ing to their onset, including visceral hyperalgesia, gastrointes-
tinal (GI) motility disturbances, environment, genetic factors,
brain-gut axis alterations, and psychosocial factors. FGIDs
are extremely frequent, with a prevalence of 23% in the
paediatric population from the European-Mediterranean
Area [2]. Due to the lack of specific markers, they are cur-
rently diagnosed according to the Rome criteria that provide
a standardized definition and classification for FGIDs. Since
the first meeting of the paediatric working team in 1997 [1],
the Rome criteria have been regularly updated [3, 4]. The
clinical advantage of using the Rome criteria is that they
allow a “positive” approach to the patient, avoiding unneces-
sary tests to rule out an organic cause, with a beneficial effect
on both patient’s health and healthcare costs. In fact, FGIDs
are associated with significant morbidity and high costs, with
influence on socialization, school absenteeism, and long-term
psychological implications, with quality of life scores compar-
able to that of subjects with inflammatory bowel disease [5],
and a significant proportion of these patients that continues
to have symptoms into adulthood [6, 7].
One of the major issues in the clinical management of
FGIDs is the treatment. Current pharmacological thera-
pies are mainly targeted at managing the predominant
symptom, with an action that could be either peripheral
(e.g. antispasmodic drugs) or central (e.g. antidepressants).
However, the long-term effectiveness of these approaches
is extremely variable. Some evidence exists on the efficacy
of centrally directed treatments, such as cognitive beha-
vioural therapy and hypnotherapy; nevertheless, these in-
terventions are time-consuming and costly, and are not
available in the majority of clinical settings. This makes
the treatment of FGIDs a great unmet need in modern
paediatric gastroenterological practice. Because of these
limited treatment options, in recent years there has been
an increase in the self-prescription of elimination diets in
subjects affected by FGIDs, especially in patients with ir-
ritable bowel syndrome (IBS). This is mainly due to the
fact that, in subjects with IBS, the perception of suffering
from a food intolerance is more common than in the gen-
eral population, with up to 60% of the patients referring
GI symptoms between 15min and 3 h after the intake of
specific foods [8]. The mechanisms by which food can
cause GI symptoms are various, including immune system
stimulation and activation of intestinal mechanoreceptors.
The hypothesis of an activation of the immune system is
supported by the evidence of an intense mast cell infiltra-
tion in intestinal biopsies of subjects with IBS [9]. An ex-
planation for this low-grade inflammation is that specific
food antigens could overcome the intestinal barrier and
stimulate an immune response, resulting in mast cell infil-
tration, release of inflammatory mediators and onset of GI
symptoms. Regarding the pathogenetic role of specific
mechanoreceptors, this is supported by the evidence that
the interaction between dietary factors and intestinal
microbiota in the gut lumen causes fermentation, gas pro-
duction and intestinal distension that, in the presence of
visceral hyperalgesia and alterations of the GI motility,
could be responsible for the onset of pain and bowel habit
changes [10].
Non-coeliac gluten sensitivity (NCGS) is characterized
by intestinal (e.g. bloating and abdominal pain) and
extra-intestinal symptoms (e.g. headache, anxiety,
fibromyalgia-like syndrome and skin rash) subsequent to
the ingestion of gluten, in subjects without coeliac dis-
ease or wheat allergy [11].
NCGS can occur at any age. However, it is rare during
childhood, arising more frequently in adulthood, with a
peak in the fourth decade of life [12]. IBS-like com-
plaints are often part of the clinical picture of NCGS,
with NCGS individuals often fulfilling the Rome criteria
for IBS, with a frequent overlap between these two con-
ditions. The main difference is that subjects with NCGS
tend to clearly identify gluten as the culprit for the
occurrence of GI symptoms, while IBS patients do not dir-
ectly correlate gluten to the symptomatology [13]. Still,
wheat is one of the foods more frequently associated with
the onset of GI symptoms in subjects with IBS.
On the other hand, it is still not clear which component
of wheat is responsible for the clinical effects: proteins (es-
pecially gluten), or carbohydrates (especially, fermentable
oligo-di-mono-saccharides and polyols – FODMAPs) [10].
However, regardless of which component is responsible
there is an agreement that wheat elimination can improve
GI symptoms in a subgroup of patients with IBS, that can
be defined as affected by wheat-sensitive IBS [13].
The aim of the present systematic review is to evaluate
the available evidence on the effects of a gluten free diet
(GFD) on GI symptoms, in subjects with FGIDs.
Methods
Search strategy and selection criteria
A computerized literature search was conducted from in-
ception to March 2018 through MEDLINE (via PubMed)
using the MeSH terms “functional gastrointestinal dis-
order OR irritable bowel syndrome AND gluten”, and
through the Cochrane Library, using the MeSH term
“functional gastrointestinal disorder” and the subheading
“diet therapy”. Trials published in English and evaluating
the effects of a GFD in subjects with FGIDs diagnosed ac-
cording to the Rome II, III, and IV criteria were included.
Trials evaluating subjects affected by coeliac disease,
wheat allergy, or other gluten-related disorders (gluten
sensitivity) were excluded. Due to the paucity of studies
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conducted on paediatric subjects, we decided to include
also studies enrolling adult subjects. Reference citations
from all the included studies were searched to add further
appropriate publications. Duplicate publications were
excluded.
Data extraction and quality assessment
Title and abstract of the included studies were inde-
pendently screened by two authors (RA and ES). Full
texts were obtained only for studies meeting the inclu-
sion criteria. The eligibility of full text articles was inde-
pendently assessed by two authors (RA and ES).
Disagreement on study eligibility were discussed and re-
solved with a third author (RT). Data from the included
studies was independently extracted by two authors (AC
and FP) using a predefined scheme. Any discrepancy be-
tween the two sets of data extracted was discussed with
a third author (ES). Two authors (AC and FP) independ-
ently evaluated the risk of bias of the selected studies
using the Cochrane risk of bias tool [14] including the
following domains: random sequence generation (selec-
tion bias), blinding of participants and personnel (per-
formance bias), allocation concealment (selection bias),
blinding of outcome assessment (detection bias), incom-
plete outcome data (attrition bias) and selective report-
ing (reporting bias), while as “other bias” we included
the lack of a control group (design bias). For each out-
come, the risk of bias was defined as “low”, “high”, or
“unclear” (Table 1).
Results
The selection process is described in Fig. 1. Starting
from the 4886 articles identified in our search, we finally
selected 11 clinical trials evaluating the effect of a GFD
on GI symptoms, in subjects with FGIDs. All the studies
were published in the past 10 years, included subjects
with IBS or FGIDs diagnosed according to the Rome cri-
teria, and excluded the presence of coeliac disease. How-
ever, 5 studies did not report the methods used to rule
out wheat allergy [15–19]. Regarding the study design, 1
study was a single-blind, randomized controlled trial
[17], 3 were prospective studies evaluating only the clin-
ical response to a GFD, without performing a gluten
challenge [15, 19, 20], while the remaining 7 studies
were double-blind placebo-controlled trials (DBPCT)
[16, 18, 21–25], and 4 of them also had a crossover de-
sign [18, 21, 23, 25].
Table 2 summarizes data regarding the study design,
inclusion criteria, outcomes, results and risk of bias of
the 11 studies included.
Prospective studies evaluating the effect of a gluten free
diet on GI symptoms
Three of the studies are prospective trials evaluating
the effect of a GFD on GI symptoms, without per-
forming a gluten challenge. Wahnschaffe et al. [15]
included 41 adult subjects with IBS to follow a GFD
for 6 months. They evaluated the HLA-DQ2 status
and the effect of the diet on stool frequency, GI
symptoms, anti-gliadin IgG and tissue-transglutami-
nase antibodies. They also recruited 102 healthy vol-
unteers as a control group for the GI symptoms.
After 6 months of GFD, 41 IBS patients showed a sig-
nificant decrease in stool frequency and GI symptom
score, that in 20/41 (49%) improved to scores within
the normal range. They also found that increased
Table 1 Risk of bias of the included studies, rated according to the Cochrane risk of bias tool, as high, unclear or low
Reference Random
sequence
generation
(Selection bias)
Allocation
concealment
(Selection bias)
Blinding of
participant
and personnel
(Performance bias)
Blinding of
outcome
assessment
(Detection bias)
Incomplete
outcome data
(Attrition bias)
Selective
reporting
(Reporting bias)
Choice of
control groups
(Bias in design)
Adult studies
Wahnschaffe et al. [14] High risk Unclear risk High risk High risk Low risk Low risk Low risk
Biesiekierski et al. [15] Low risk Low risk Low risk Low risk High risk Low risk High risk
Vazquez-Roche et al. [16] Low risk High risk High risk High risk Low risk High risk High risk
Biesiekierski et al. [17] Low risk High risk Low risk Low risk High risk Low risk High risk
Aziz et al. [18] High risk High risk High risk High risk Low risk Low risk High risk
Barmeyer et al. [19] High risk Low risk High risk High risk Low risk Low risk High risk
Carroccio et al. [20] High risk Low risk Low risk Low risk Low risk Low risk Low risk
Shahbazkhani et al. [21] Low risk Low risk Low risk Low risk Low risk Low risk Low risk
Elli et al. [22] Low risk Low risk Low risk Low risk Low risk Low risk High risk
Zanwar et al. [23] Low risk Low risk Low risk Low risk High risk Low risk Unclear risk
Paediatric studies
Francavilla et al. [25] Low risk Low risk Low risk Unclear Unclear Low risk Low risk
Scarpato et al. Italian Journal of Pediatrics            (2019) 45:9 Page 3 of 11
anti-gliadin (AGA) IgG and/or tissue-transglutaminase
antibodies were more frequent in IBS patients who
expressed the HLA-DQ2 compared to HLA-DQ2–
negative IBS patients (P < .05) and that a normal GI
symptom score after GFD was achieved more fre-
quently in those patients who were HLA-DQ2-posi-
tive and/or had celiac disease–associated IgG
antibodies. Finally, diarrhea resolved more frequently
4886 articles identified through Pubmed 
and Cochrane's Library search
89 eligible articles on gluten free diet in 
subjects with IBS/FGIDs
11 articles on gluten free diet in subjects 
with IBS/FGIDs, diagnosed according to 
the Rome criteria  
78 articles excluded after text review
- reviews
- case reports
- self-reported GI symptoms
- studies evaluating only mucosal changes
4797 articles excluded after title and 
abstract screening
- coeliac disease
- wheat allergy
- non-English language
Fig. 1 Flow chart of the literature search
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in HLADQ2–positive patients with celiac disease–as-
sociated IgG antibodies. According to their data,
serum AGA IgG or tissue-transglutaminase antibodies
in combination with HLA-DQ2 expression could be
useful to identify a subgroup of patients with IBS
more likely to respond to a GFD. These findings are
in contrast with the results of the second prospective
trial, performed in 2016 by Aziz et al. [19], who eval-
uated the HLA DQ2/8 status and the GI symptom
score of 41 adults with IBS-diarrhea who were asked
to follow a GFD for 6 weeks. At the end of the GFD,
29/41 (71%) subjects showed a significant reduction
of the IBS-Symptom Severity Score (IBS-SSS), irre-
spective of the HLA-DQ2/8 status. Their findings are
similar to the ones of Barmeyer et al. [20] that en-
rolled 35 adults with IBS to evaluate overall
well-being and GI symptoms response to a 4-months
GFD, in relation to HLA DQ2/8 status. At the end of
the 4-months follow-up, 12/35 (34%) subjects had a
significant improvement of the subject’s global assess-
ment and were classified as having a wheat sensitivity,
with 3/12 (25%) that reached a complete relief. How-
ever, no association was found between HLA-DQ2/8
expression and wheat sensitivity. Data from all the
trials are summarized in Table 2.
Single and double blind, placebo controlled trials
evaluating the effect of gluten on GI symptoms
Adult studies
Seven studies are controlled trials, with a single or a
double-blind design, evaluating the effect of gluten on GI
symptoms, in adults. In 2011 Biesiekierski et al. [16] per-
formed a DBPCT in 34 adult patients with IBS. According
to the study protocol, all subjects had to follow a GFD
throughout the study period and were asked to consume,
every day for 6 weeks, one muffin and two slices of bread
with or without gluten. The primary outcome was the
symptom control, assessed with a specific question, while
the secondary outcome was the change in overall and in-
dividual GI symptoms (bloating, abdominal pain, satisfac-
tion with stool consistency, nausea and tiredness) assessed
with a visual analog scale (VAS). They also evaluated the
HLA-DQ2/8 status of the patients included. At the end of
the study, 13/19 (68%) patients in the gluten group re-
ported poor symptom control compared to 6/15 (40%) in
the placebo group (P < .001). Moreover, patients in the
gluten group had greater changes in overall symptoms
from baseline to the end of week 1, and higher severity
scores over the entire study period than those in the
placebo group. The symptomatic response to gluten was
not influenced by HLA status. However, in 2013 the same
research group performed a new DBPCT on 37 adult sub-
jects with IBS to evaluate the specific effects of gluten
after dietary reduction of FODMAPs [18]. All the patients
followed a low FODMAPs diet for a 2-weeks run-in
period and were then asked to continue a GFD low in
FODMAPs for the entire study period. All patients re-
ceived 1 of 3 diets (high or low gluten, or placebo) for 1
week and, after a washout period, had to crossover to an-
other intervention. A re-challenge was also performed,
during which all subjects received 1 of 3 diets (gluten,
whey, or placebo) for 3 days, followed by a washout before
crossing over to the next intervention. Symptom score
was evaluated on a VAS. Considering the 7-days trial, the
average of symptoms improved already during the second
week of the low FODMAPs diet, with 8/37 (22%) subjects
showing a significant improvement compared to baseline,
and only 6/37 (16%) having an increase in overall symp-
toms during the high-gluten diet. It was not possible to
observe a dose effect of gluten, with a symptomatic re-
sponse to gluten identified in only 3/37 (8%) and with 11/
37 (30%) showing a positive response in the placebo arm.
During the 3-days re-challenge, changes in individual
symptoms were similar across the 3 dietary interventions
(all P > .209), with gluten specificity that was not repro-
duced in any subject. Another trial published in 2012 [21]
is a retrospective chart review that included 276 subjects
with an IBS-like presentation and non-coeliac wheat
sensitivity (NCWS) diagnosed with a DBPC challenge.
Notably, the original cohort included 920 IBS patients
who underwent an elimination diet followed by a DBPC
re-challenge, finding that 276/920 (30%) had symptoms
during gluten ingestion. Subjects with NCWS were di-
vided in 2 groups: 70 with wheat sensitivity (WS) alone,
and 206 with WS and multiple food hypersensitivity
(MFH). HLA-DQ status and serum AGA were also evalu-
ated. All subjects had to follow a 4-weeks diet with the ex-
clusion of cow ‘s milk, wheat, eggs, tomato, and chocolate.
Considering wheat reintroduction, the DBPC re-challenge
was performed using wheat or xylose for 2 weeks, followed
by a 1-week washout before crossing over to the other
treatment. GI symptoms were evaluated on a VAS. Me-
dian time for a clinical reaction after gluten ingestion was
3 days for WS-alone subjects and 2.5 days for those with
WS and multiple food hypersensitivity. Moreover, 10 pa-
tients with WS alone and 32 with WS-MFH did not
complete the challenge due to the severity of symptoms
during wheat assumption. In all subjects, starting from 1
week after reintroduction of wheat, the VAS for GI
symptoms was significantly higher compared to baseline
(P < .0001). In addition, subjects with WS had higher rates
of positive AGA IgA and IgG compared to IBS subjects
without WS (P = .0001 and P = .0001, respectively), and
subjects with WS alone had a higher frequency of HLA
DQ2 or DQ8 positivity compared to subjects with
WS-MFH (P = .0001). The only single-blind trial included
is a study from Vazquez-Roche et al. [17], in which 45
subjects with IBS-D were enrolled to follow a 4-weeks
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gluten containing/free diet. The primary outcome was to
evaluate the effect on bowel frequency and form. They
also performed HLA genotyping of DQ alleles, measure-
ment of gastric emptying, small bowel and colonic transit,
permeability and morphology, quantitation of tight junc-
tion proteins, and evaluation of proliferative responses of
peripheral blood mononuclear cells’ (PBMCs) cytokines to
gluten and rice. Their data showed a significant decrease
in stool frequency during the GFD compared to the gluten
containing diet (P = .04), with a greater effect in
HLA-DQ2 or DQ8 positive subjects. No diet effect on
stool form, gastric emptying, colonic transit, mucosal
morphology, and PBMCs proliferation was found. On the
contrary, they reported a change in occludin expression in
the small bowel mucosa of HLA-DQ2 or DQ8 subjects as-
sociated to the GFD, an increased small bowel permeabil-
ity during the gluten containing diet, and a greater
induction of IL-10 by PBMCs when stimulated with glu-
ten compared to rice (P < .01). Subsequently, in 2015,
Shahbazkhani et al. [22] performed a DBPCT on 72 adult
subjects with IBS to evaluate the effect of gluten on GI
symptoms. Patients were asked to follow a 6-weeks GFD
during which a gluten or placebo meal was assumed daily.
HLA-DQ status was also studied in all the patients. At the
end of the trial statistically significant differences between
the gluten containing and the gluten free groups were de-
scribed regarding the symptoms control (P < .001), with
no effect of HLA status. In 2016, Elli et al. [23] performed
another DBPCT on 98 adult patients with functional GI
symptoms to study the effect of gluten on satisfaction
level, general well-being, and GI symptom severity, evalu-
ated on a VAS. During the run-in phase patients had to
follow a GFD for 3 weeks and, in case of a positive re-
sponse, were enrolled to perform the DBPC gluten chal-
lenge, followed by a 7-days washout period before
crossing over to the other treatment. During the gluten
challenge, a worsening of general well-being was reported
more frequently in the gluten group than in the placebo
group (P = .05). Twenty-eight/98 (28.5%) relapsed during
gluten administration, with 14/28 (50%) that were respon-
sive also to placebo administration (nocebo effect). So,
only 14/98 (14.2%) relapsed exclusively during the gluten
challenge. The last DBPCT was published in 2016 by Zan-
war et al. [24] who enrolled 60 adults with IBS to evaluate
their clinical response to gluten administration. Overall
and individual symptoms were evaluated on a VAS. All
subjects had to follow a GFD for 4 weeks and, those who
had an adequate response, were included in the
double-blind gluten challenge after a 4-weeks washout. A
greater worsening of symptoms was reported in the gluten
group compared to the placebo group (P < .05) for both
overall and individual symptoms, with the only exception
of wind passage. All the details regarding the studies’
procedures are summarized in Table 2.
Paediatric studies
There is only one DBPC gluten challenge performed in
children with chronic functional GI symptoms and pub-
lished in January 2018 by Francavilla et al. [25]. In their
study, the researchers screened 1114 children with func-
tional GI symptoms diagnosed according to Rome III
criteria, to evaluate the correlation between symptoms
and gluten ingestion. Thirty-six out of 1114 (3.3%)
subjects self-reported an association between gluten
assumption and symptoms occurrence. GI symptoms’ se-
verity was assessed by a VAS and by the IBS-SSS, while
the impact on quality of life was evaluated using the
State-Trait Anxiety Inventory for Children (STAIC).
Five/36 (13.9%) subjects had a spontaneous improve-
ment of symptoms during the run-in phase, before the
beginning of the DBPC trial. Subsequently, 31 subjects
were included in the open 2-weeks GFD, after which
subjects with a significant reduction in GI symptoms
were enrolled for the placebo-controlled gluten
challenge. Twenty-eight children were enrolled for the
gluten re-challenge, with the administration of one sa-
chet each day of gluten (10 g/day) or placebo (rice
starch) for 2 weeks, followed by the crossover to the
other treatment group for other 2 weeks, after a 1-week
wash-out period. At the end of the trial, the authors re-
ported a decrease in all clinical scores during the open
GFD, with 11/28 (39.2%) having a global VAS improve-
ment > 30% between the gluten and the placebo chal-
lenge. However, no difference in the global VAS score
was found during the blind administration of gluten or
placebo, and 4/36 (14.3%) had an increase of symptoms
during the placebo administration.
Gluten and placebo challenge
Regarding the gluten challenge, the methods widely vary
among the different studies. In fact, the specific amount of
gluten administered ranges from 5.6 g/d [23] to 52 g/d [22],
and sometimes is not even specified [17, 24]. Only 1 study
used an unspecified amount of wheat instead of gluten [21].
Differences exist also regarding the type of placebo used in
the 7 trials in which a gluten challenge was performed, in-
cluding whey [18], xylose [21], rice starch alone [17, 23, 25]
or combined with corn starch and glucose [22], or gluten
free muffins and/or bread [16, 24]. Moreover, variability is
also found in the duration of the challenge (from 1 to 6
weeks), of the washout period (from 1 to 2 weeks), and of
the GFD (from 6weeks prior the challenge to a total of 6
months). Finally, in the study by Carroccio et al. [21] the
GFD is combined with an exclusion of cow’s milk, eggs, to-
mato, and chocolate; in the study by Biesikierski et al. [18]
the GFD diet is associated with a low FODMAPs diet, while
in the trial by Shahbazkhani et al. [22] the gluten meal used
in the re-challenge is free of FODMAPs. Detailed informa-
tion on the study procedures are summarized in Table 2.
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Discussion
In this systematic review we have included 11 studies
that evaluated the clinical response to gluten in subjects
with FGIDs. The risk of bias of the studies ranges from
low to high, the latter mainly due to the lack of exclu-
sion of wheat allergy in the subjects enrolled and to the
blinding of participants [15–19]. Most of the studies
included in this systematic review have identified a cor-
relation between GI symptoms occurrence and gluten
administration.
In recent years, the number of subjects following a
GFD has increased exponentially ranging from 6.2–13%
of the general population [13]. This is partly linked to
the association of gluten intake with GI symptoms, and
partly due to the perception of the GFD as healthier
compared to a standard diet, even for people who are
not affected by coeliac disease or wheat allergy. How-
ever, although the GFD is generally regarded as a safe
long-term diet, it is important to note that it is not
risk-free in terms of nutritional adequacy. In fact, it has
been demonstrated that GFD can be associated with
lower intakes of micronutrients (iron, calcium, magne-
sium, and vitamin D) and carbohydrates, and higher in-
takes of saturated fats, simple sugars and proteins,
compared to the recommended daily intakes [26]. For
this reason, it is important to recommend a GFD only to
those subjects who can really benefit from it.
According to the prospective studies included, GFD
seems to have an effect on overall GI symptoms control
in subjects with FGIDs, reporting a significant decrease
in GI symptoms in 29–71% of the subjects enrolled [15,
19, 20], with Whanschaffe et al. [15] describing also an
improvement in stool consistency in 37% of the IBS-D
subjects enrolled. However, these are prospective studies
with a high risk of bias, carried on without blinding of
the participants to the intervention, and without the
possibility to minimize the placebo effect that is one of
the major contributors to the clinical response in trials
performed on subjects with IBS, with a response rate
that can reach 42% [27]. Placebo effect in IBS trials
seems not to be influenced by the trial duration, with
evidence reporting rates of 40% of placebo response
even after 52 weeks of treatment. In addition, the pla-
cebo effect in FGIDs seems to be higher in children
compared to adolescents and adults [28].
Regarding As regards the gluten re-challenges, most of
the studies included found a correlation between gluten
ingestion and decreased control of GI symptoms in
28.5–100% of the patients evaluated. Biesiekierski et al.
[16], Carroccio et al. [21] and Shahbazkhani et al. [22]
described that the worsening of symptoms tends to
occur within 1 week from gluten reintroduction.
Nevertheless, Biesiekierski et al. [18] failed to describe
an association between gluten and GI symptoms, if
FODMAPs content was simultaneously reduced in the
diet, while Francavilla et al. [25] found no difference in
GI symptoms control during the blind administration of
gluten or placebo, reporting a worsening of symptoms in
14% of the subjects even during placebo treatment.
In 3 of the trials [16, 17, 21] the effect of gluten on bowel
pattern was also evaluated, finding an improvement in pa-
tients’ satisfaction with stool consistency. Of note, Elli et al.
[23] found that 28.5% of the patients relapsed during the
gluten challenge, but 50% of these subjects referred a wor-
sening of symptoms also during placebo assumption, simi-
larly to what reported by Francavilla et al. regarding GI
symptoms, in children [25]. These finding could be related
to the nocebo effect that has been described in subjects
with FGID, especially those referring a food intolerance,
with symptoms that tend to be more present at home com-
pared to the laboratory setting [28]. This systematic review
presents some limitations. One of the major issues is re-
lated to the difficulty to compare the results of the different
trials due to discrepancies in the study protocols. The first
difference concerns the amount and type of gluten adminis-
tered. As suggested by Catassi et al. [29], the dose of gluten
for the challenge should be of 8 g/d, since this amount is
not far from the average intake in the Western diet (10–15
g). However, 3 of the studies do not specify the amount of
gluten administered [17, 21, 24], while 1 study uses lower
doses [23]. In addition, in 3 of the trials gluten is adminis-
tered as bread [24] and/or muffins [16], or as wheat [21],
which makes it impossible to exclude the presence of other
components that could be responsible for the symptoms. In
fact, it is still not clear which component of wheat is harm-
ful for subjects with IBS: gluten, amylase/trypsin inhibitors
(ATIs), wheat germ agglutinins (WGA), or FODMAPs [13].
ATIs are wheat proteins with a protective role against para-
sites that can also act as triggers for the innate immunity
via the Toll-like receptor 4 [30], while WGA are protective
proteins contained in wheat grains that can induce the re-
lease of pro-inflammatory cytokines and alter the integrity
of the intestinal epithelium, without an immune stimulatory
activity [13]. Finally, FODMAPs include short chain carbo-
hydrates that are not adsorbed in the small intestine, with
subsequent fermentation and osmotic action in the large
intestine [31]. As demonstrated by Biesikierski et al. in 2013
[18], a specific effect of gluten on GI symptoms was not
confirmed after elimination of FODMAPs from the diet.
All the abovementioned components have been associated
to the occurrence of GI symptoms. The effect of FOD-
MAPs restriction in GI symptoms’ control has been ad-
dressed in another systematic review performed on behalf
of the Italian Society of Paediatrics by Turco et al. [32].
In addition, differences exist regarding the amount
and duration of the gluten challenges, the type of
placebo administered and the duration of the challenge
itself. Moreover, in some of the trials the washout period
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lasts for only 1 week, that might not be sufficient to ex-
clude the effects of previous interventions, especially in
case of a cross-over design. Discrepancies exist also re-
garding the scoring scales used to assess GI symptoms.
For this reason, it would be preferable that further
studies are conducted using standardized and validated
questionnaires to assess GI symptoms.
Conclusions
In conclusion, our systematic review shows that gluten,
and more probably wheat in general, can contribute to
the occurrence of GI symptoms in a subgroup of
patients with FGIDs, particularly in adults with IBS.
However, the results of the trials available are difficult to
compare due to the lack of standardization in the study
designs. In children, there is only one DBPCT available
and more studies are needed to draw convincing conclu-
sions on the role of GFD for the management of GI
symptoms. For this reason, currently it is not possible to
recommend the use of the GFD in the routine manage-
ment of FGIDs in adults and children.
Abbreviations
AGA: Anti-gliadin; ATIs: Amylase/trypsin inhibitors; DBPCT: Double-blind
placebo-controlled trials; FGIDs: Functional gastrointestinal disorders;
FODMAPs: Fermentable oligo-di-mono-saccharides and polyols; GFD: Gluten
free diet; GI: Gastrointestinal; IBS: Irritable bowel syndrome; IBS-SSS: IBS-
Symptom Severity Score; MFH: Multiple food hypersensitivity; NCGS:
Non-coeliac gluten sensitivity; NCWS: Non-coeliac wheat sensitivity;
PBMCs: Peripheral blood mononuclear cells’; VAS: Visual analog scale;
WGA: Wheat germ agglutinins; WS: Wheat sensitivity
Acknowledgements
Not applicable.
Funding
Not applicable.
Availability of data and materials
Not applicable.
Authors’ contributions
ES: performed the literature search, interpreted the results, drafted the initial
manuscript, approved the final manuscript as submitted, and is accountable
for all aspects of the work; RA: acquired the data and interpreted the results,
drafted the initial manuscript, approved the final manuscript as submitted,
and is accountable for all aspects of the work; FP: interpreted the data,
critically reviewed the final manuscript for important intellectual content,
approved the final manuscript as submitted, and is accountable for all
aspects of the work; AC: interpreted the data, critically reviewed the final
manuscript for important intellectual content, approved the final manuscript
as submitted, and is accountable for all aspects of the work; GVZ:
contributed to conception and design of the review, reviewed the final
manuscript for important intellectual content, approved the final manuscript
as submitted, and is accountable for all aspects of the work; RT: contributed
to conception and design of the review, reviewed the final manuscript for
important intellectual content, approved the final manuscript as submitted,
and is accountable for all aspects of the work.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Translational Medical Sciences – Section of Paediatrics,
University of Naples Federico II, via Pansini 5, 80131 Naples, Italy.
2Department of Pediatrics, University of Milan, V. Buzzi Children’s Hospital, via
Castelvetro 32, 20154 Milan, Italy. 3Pediatrics, Department of Medical and
Surgical Sciences, University of Foggia, via Luigi Pinto 1, 71100 Foggia, Italy.
Received: 8 May 2018 Accepted: 3 January 2019
References
1. Rasquin-Weber A, Hyman PE, Cucchiara S, Fleisher DR, Hyams JS, Milla PJ,
Staiano A. Childhood functional gastrointestinal disorders. Gut. 1999;45:II60–8.
2. Scarpato E, Kolacek S, Jojkic-Pavkov D, Konjik V, Živković N, Roman E, et al.
Prevalence of Functional gastrointestinal Disorders in children and
adolescents in the Mediterranean region of Europe. Clin Gastroenterol
Hepatol. 2017. https://doi.org/10.1016/j.cgh.2017.11.005.
3. Rasquin A, Di Lorenzo C, Forbes D, Guiraldes E, Hyams JS, Staiano A, Walker
LS. Childhood functional gastrointestinal disorders: child/adolescent.
Gastroenterology. 2006;130(5):1527–37.
4. Hyams JS, Di Lorenzo C, Saps M, Shulman RJ, Staiano A, van Tilburg M.
Functional Disorders: Children and adolescents. Gastroenterology. 2016.
https://doi.org/10.1053/j.gastro.2016.02.015.
5. Youssef NN, Murphy TG, Langseder AL, Rosh JR. Quality of life for children
with functional abdominal pain: a comparison study of patients’ and
parents’ perceptions. Pediatrics. 2006;117:54–9.
6. Campo JV, Di LC, Chiappetta L, Bridge J, Colborn DK, Gartner JC Jr, et al.
Adult outcomes of pediatric recurrent abdominal pain: do they just grow
out of it? Pediatrics. 2001;108:E1.
7. Walker LS, Guite JW, Duke M, Barnard JA, Greene JW. Recurrent abdominal
pain: a potential precursor of irritable bowel syndrome in adolescents and
young adults. J Pediatr. 1998;132:1010–5.
8. Simrén M, Månsson A, Langkilde AM, Svedlund J, Abrahamsson H,
Bengtsson U, Björnsson ES. Food-related gastrointestinal symptoms in the
irritable bowel syndrome. Digestion. 2001;63:108–15.
9. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, et al.
Activated mast cells in proximity to colonic nerves correlate with abdominal
pain in irritable bowel syndrome. Gastroenterology. 2004;126:693–702.
10. De Giorgio R, Volta U, Gibson PR. Sensitivity to wheat, gluten and FODMAPs
in IBS: facts or fiction? Gut. 2016;65:169–78.
11. Volta U, Caio G, Karunaratne TB, Alaedini A, De Giorgio R. Non-coeliac
gluten/wheat sensitivity: advances in knowledge and relevant questions.
Expert Rev Gastroenterol Hepatol. 2017;11(1):9–18.
12. Volta U, Bardella MT, Calabrò A, Troncone R, Corazza GR. The study Group
for non-Celiac Gluten Sensitivity. An Italian prospective multicenter survey
on patients suspected of having non-celiac gluten sensitivity. BMC Med.
2014;12:85.
13. Catassi C, Alaedini A, Bojarski C, Bonaz B, Bouma G, Carroccio A, et al. The
overlapping area of non-celiac gluten sensitivity (NCGS) and wheat-sensitive
irritable bowel syndrome (IBS): an update. Nutrients. 2017. https://doi.org/
10.3390/nu9111268.
14. Higgins JPT, Green S. Cochrane handbook for systematic reviews of
interventions, version 5.1.0 (update march 2011). The Cochrane
Collaboration, 2011. Available at: www. cochrane-handbook.org.
15. Wahnschaffe U, Schulzke JD, Zeitz M, Ullrich R. Predictors of clinical
response to gluten-free diet in patients diagnosed with diarrhea-
predominant irritable bowel syndrome. Clin Gastroenterol Hepatol. 2007;
5(7):844–50.
16. Biesiekierski JR, Newnham ED, Irving PM, Barrett JS, Haines M, Doecke JD, et
al. Gluten causes gastrointestinal symptoms in subjects without celiac
disease: a double-blind randomized placebo-controlled trial. Am J
Gastroenterol. 2011;106(3):508–14.
17. Vazquez-Roque MI, Camilleri M, Smyrk T, Murray JA, Marietta E, O'Neill J, et
al. A controlled trial of gluten-free diet in patients with irritable bowel
Scarpato et al. Italian Journal of Pediatrics            (2019) 45:9 Page 10 of 11
syndrome-diarrhea: effects on bowel frequency and intestinal function.
Gastroenterology. 2013;144(5):903–911.e3.
18. Biesiekierski JR, Peters SL, Newnham ED, Rosella O, Muir JG, Gibson PR. No
effects of gluten in patients with self-reported non-celiac gluten sensitivity
after dietary reduction of fermentable, poorly absorbed, short-chain
carbohydrates. Gastroenterology 2013;145(2):320–8.e1–3.
19. Aziz I, Trott N, Briggs R, North JR, Hadjivassiliou M, Sanders DS. Efficacy of a
gluten-free diet in subjects with irritable bowel syndrome-diarrhea unaware
of their HLA-DQ2/8 genotype. Clin Gastroenterol Hepatol. 2016;14:696–703.
20. Barmeyer C, Schumann M, Meyer T, Zielinski C, Zuberbier T, Siegmund B, et
al. Long-term response to gluten-free diet as evidence for non-celiac wheat
sensitivity in one third of patients with diarrhea-dominant and mixed-type
irritable bowel syndrome. Int J Color Dis. 2017;32(1):29–39.
21. Carroccio A, Mansueto P, Iacono G, Soresi M, D'Alcamo A, Cavataio F, et al.
Non-celiac wheat sensitivity diagnosed by double-blind placebo-
controlled challenge: exploring a new clinical entity. Am J
Gastroenterol. 2012;107(12):1898–906.
22. Shahbazkhani B, Sadeghi A, Malekzadeh R, Khatavi F, Etemadi M, Kalantri E,
et al. Non-celiac gluten sensitivity has narrowed the Spectrum of irritable
bowel syndrome: a double-blind randomized placebo-controlled trial.
Nutrients. 2015;7(6):4542–54.
23. Elli L, Tomba C, Branchi F, Roncoroni L, Lombardo V, Bardella MT, et al.
Evidence for the presence of non-celiac gluten sensitivity in patients with
Functional gastrointestinal symptoms: results from a multicenter randomized
double-blind placebo-controlled gluten challenge. Nutrients. 2016;8(2):84.
24. Zanwar VG, Pawar SV, Gambhire PA, Jain SS, Surude RG, Shah VB, et al.
Symptomatic improvement with gluten restriction in irritable bowel
syndrome: a prospective, randomized, double blinded placebo controlled
trial. Intest Res. 2016;14(4):343–50.
25. Francavilla R, Cristofori F, Verzillo L, Gentile A, Castellaneta S, Polloni C, et al.
Randomized double-blind placebo-controlled crossover trial for the
diagnosis of non-celiac gluten sensitivity in children. Am J Gastroenterol.
2018;113(3):421–30.
26. Penagini F, Dilillo D, Meneghin F, Mameli C, Fabiano V, Zuccotti GV. Gluten-
free diet in children: an approach to a nutritionally adequate and balanced
diet. Nutrients. 2013;5(11):4553–65.
27. Dorn SD, Kaptchuk TJ, Park JB, Nguyen LT, Canenguez K, Nam BH, et al. A
meta-analysis of the placebo response in complementary and alternative
medicine trials of irritable bowel syndrome. Neurogastroenterol Motil. 2007;
19(8):630–7.
28. Elsenbruch S, Enck P. Placebo effects and their determinants in
gastrointestinal disorders. Nat Rev Gastroenterol Hepatol. 2015;12(8):472–85.
29. Catassi C, Elli L, Bonaz B, Bouma G, Carroccio A, Castillejo G, et al. Diagnosis
of non-celiac gluten sensitivity (NCGS): the Salerno experts’ criteria.
Nutrients. 2015;7(6):4966–77.
30. Junker Y, Zeissig S, Kim SJ, Barisani D, Wieser H, Leffler DA, et al. Wheat
amylase trypsin inhibitors drive intestinal inflammation via activation of toll-
like receptor 4. J Exp Med. 2012;209:2395–408.
31. Staudacher HM, Irving PM, Lomer MC, Whelan K. Mechanisms and efficacy
of dietary FODMAP restriction in IBS. Nat Rev Gastroenterol Hepatol. 2014;
11(4):256–66.
32. Turco R, Salvatore S, Miele E, Romano C, Marseglia GL, Staiano A. Does a
low FODMAPs diet reduce symptoms of functional abdominal pain
disorders? A systematic review in adult and paediatric population, on behalf
of Italian Society of Pediatrics. Ital J Pediatr. 2018;44(1):53.
Scarpato et al. Italian Journal of Pediatrics            (2019) 45:9 Page 11 of 11
